Breaking News Instant updates and real-time market news.

CLBS

Caladrius

$5.92

0.14 (2.42%)

, APTO

Aptose Biosciences

$3.67

-0.06 (-1.61%)

04:55
03/17/18
03/17
04:55
03/17/18
04:55

B. Riley FBR to hold a symposium

Inaugural China Healthcare Investing & Partnering Symposium to be held in Hangzhou, China on March 15-17.

CLBS

Caladrius

$5.92

0.14 (2.42%)

APTO

Aptose Biosciences

$3.67

-0.06 (-1.61%)

EYES

Second Sight

$1.96

0.06 (3.16%)

TNXP

Tonix Pharmaceuticals

$3.54

0.08 (2.31%)

DRNA

Dicerna

$13.00

-0.49 (-3.63%)

ALT

Altimmune

$1.63

-0.08 (-4.68%)

SRTS

Sensus Healthcare

$5.87

-0.02 (-0.34%)

  • 17

    Mar

  • 20

    Mar

  • 22

    Mar

  • 27

    Mar

CLBS Caladrius
$5.92

0.14 (2.42%)

03/07/18
HCWC
03/07/18
NO CHANGE
Target $12
HCWC
Buy
Caladrius price target raised to $12 from $7 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Caladrius Biosciences (CLBS) to $12 after the company acquired from Shire (SHPG) an exclusive worldwide license to data and regulatory filings for a late-stage CD34+ cell therapy program for the treatment of chronic myocardial ischemia targeting refractory angina. The deal "significantly enriches" Caladrius' existing pipeline and should provide an "additional attractive shot on goal" in the coming years, Selvaraju tells investors in a research note. He increased his valuation of the company to $120M from $60M and reiterates a Buy rating on the shares.
APTO Aptose Biosciences
$3.67

-0.06 (-1.61%)

10/23/17
ROTH
10/23/17
INITIATION
Target $5
ROTH
Buy
Aptose Biosciences resumed with a Buy at Roth Capital
Roth Capital analyst Jotin Marango resumed Aptose Biosciences with a Buy rating and $5 price target as he sees fundamental value discounted due to formulation and manufacturing mishaps.
12/13/17
HCWC
12/13/17
NO CHANGE
Target $6
HCWC
Buy
Aptose Biosciences price target raised to $6 from $4 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Aptose Biosciences to $6 saying the company's collaborators at the American Society of Hematology annual meeting presented a broad set of preclinical data, which provides a "nice boost" to the profile of CG'806. The analyst keeps a Buy rating on Aptose.
09/07/17
HCWC
09/07/17
UPGRADE
Target $4
HCWC
Buy
Aptose Biosciences upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis upgraded Aptose Biosciences to Buy and raised his price target for the shares to $4 from $1. Having finalized manufacturing for CG'806 in a timely manner, Aptose can now further solidify its projected timeline for getting the drug into the clinic, Pantginis tells investors in a research note. The analyst increased his projected chance of success for CG'806 to 7% from 5%.
06/08/17
RODM
06/08/17
INITIATION
Target $1
RODM
Neutral
Aptose Biosciences initiated with a Neutral at Rodman & Renshaw
Rodman & Renshaw analyst Joseph Pantginis started Aptose Biosciences with a Neutral rating and $1.00 price target. The analyst sees a lack of meaningful catalysts for the remainder of 2017.
EYES Second Sight
$1.96

0.06 (3.16%)

TNXP Tonix Pharmaceuticals
$3.54

0.08 (2.31%)

08/18/17
ROTH
08/18/17
UPGRADE
ROTH
Buy
Tonix Pharmaceuticals upgraded to Buy from Neutral at Roth Capital
08/18/17
ROTH
08/18/17
UPGRADE
ROTH
Buy
Tonix Pharmaceuticals upgraded to Buy on valuation at Roth Capital
As previously reported, Roth Capital upgraded Tonix to Buy from Neutral with a price target of $6. Analyst Scott Henry believes Tonix's current valuation does not reflect the potential of the Tonmya program to treat PTSD and said the company has the cash runway to reach pivotal data readout in both first half 2018 and second half 2018. Additionally, the analyst said the AtEase trial has a reasonable chance for success with the higher 5 6 mg dose.
08/18/17
08/18/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. United Rentals (URI) upgraded to Buy from Hold at Stifel with analyst Stanley Elliott saying that the company's acquisition of Neff (NEFF) increases his confidence in its outlook and leaves it better positioned to exploit favorable demand trends. 2. Tonix Pharmaceuticals (TNXP) upgraded to Buy from Neutral at Roth Capital with analyst Scott Henry believes Tonix's current valuation does not reflect the potential of the Tonmya program to treat PTSD and said the company has the cash runway to reach pivotal data readout in both first half 2018 and second half 2018. 3. Quanta Services (PWR) and MasTec (MTZ) were upgraded to Buy from Neutral at Citi. 4. Howard Bancorp (HBMD) upgraded to Overweight from Equal Weight at Stephens with analyst Austin Nicholas saying the in-market acquisition of 1st Mariner strategically deploys Howard's excess capital, creating the #1 community bank in Baltimore. 5. Myriad Genetics (MYGN) upgraded to Hold from Sell at Deutsche Bank with analyst Dan Leonard saying the risk/reward is now balanced following the company's weaker than expected FY18 outlook. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/22/17
DRXL
08/22/17
INITIATION
Target $9
DRXL
Buy
Tonix Pharmaceuticals initiated with a Buy at Drexel Hamilton
Drexel Hamilton initiated Tonix Pharmaceuticals with a Buy and a $9 price target.
DRNA Dicerna
$13.00

-0.49 (-3.63%)

02/05/18
RHCO
02/05/18
INITIATION
Target $13
RHCO
Buy
Dicerna initiated with a Buy at SunTrust
SunTrust analyst Edward Nash initiated Dicerna (DRNA) with a Buy rating and a price target of $13. Nash says Dicerna is a "a pure-play platform technology company" whose lead program is in a Phase I development targeting a rare disease - primary hyperoxaluria - affecting some 2,700 people in the U.S. and Europe. The analyst adds that he "would not be surprised" to see a positive outcome from Dicerna's patent litigation with Alnylam (ALNY) expected this spring.
01/16/18
01/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Axalta Coating (AXTA) resumed with an Underperform at BofA/Merrill. 2. UBS (UBS) and Credit Suisse (CS) were initiated with an Underweight at Barclays. 3. Nutrien (NTR) initiated with a Neutral at Goldman Sachs. 4. Cambrex (CBM) initiated with an Outperform at William Blair. 5. Dicerna (DRNA) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/16/18
EVER
01/16/18
INITIATION
Target $14
EVER
Outperform
Dicerna initiated with an Outperform at Evercore ISI
Evercore ISI analyst Umer Raffat initiated Dicerna with an Outperform and $14 price target.
11/03/17
HCWC
11/03/17
NO CHANGE
Target $10
HCWC
Buy
Dicerna price target raised to $10 from $6 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Dicerna Pharmaceuticals to $10 saying the company partnered a single early discovery asset for over $200M in upfront and milestones. The analyst reiterates a Buy rating on the shares.
ALT Altimmune
$1.63

-0.08 (-4.68%)

10/09/17
PIPR
10/09/17
INITIATION
Target $6
PIPR
Overweight
Altimmune initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Charles Duncan started Altimmune with an Overweight rating and $6 price target. The analyst sees NasoVAX, an intranasal recombinant vaccine in seasonal influenza, as "potentially differentiated" on efficacy and breadth of immune response, efficient manufacturing, and painless administration versus current options.
10/09/17
10/09/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ctrip.com (CTRP) initiated with an Overweight at Barclays. 2. Yum China (YUMC) initiated with a Buy at Nomura Instinet. 3. Onconova (ONTX) initiated with a Buy at H.C. Wainwright. 4. Altimmune (ALT) initiated with an Overweight at Piper Jaffray. 5. Equity Lifestyle (ELS) was initiated with a Market Perform while Sun Communities (SUI) was initiated with an Outperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
SRTS Sensus Healthcare
$5.87

-0.02 (-0.34%)

06/06/17
MAXM
06/06/17
INITIATION
Target $6.5
MAXM
Buy
Sensus Healthcare initiated with a Buy at Maxim
Maxim analyst Anthony Vendetti started Sensus Healthcare with a Buy rating and $6.50 price target, as he views SRT-100 and SRT-100 Vision as viable options to treat non-melanoma skin cancers and sees signals that this treatment is re-emerging.

TODAY'S FREE FLY STORIES

DB

Deutsche Bank

$14.46

0.015 (0.10%)

, DBOEY

Deutsche Boerse

06:15
04/20/18
04/20
06:15
04/20/18
06:15
Periodicals
Deutsche Bank blames 'operational error' for accidental EUR28B transfer, FT says »

Deutsche Bank (DB) has…

DB

Deutsche Bank

$14.46

0.015 (0.10%)

DBOEY

Deutsche Boerse

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

SWK

Stanley Black & Decker

$154.68

-2.715 (-1.73%)

06:12
04/20/18
04/20
06:12
04/20/18
06:12
Hot Stocks
Stanley Black & Decker executed equity derivative deal to lock buyback pricing »

During Q1, Stanley Black…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 04

    Jun

PG

Procter & Gamble

$74.98

-2.4928 (-3.22%)

06:12
04/20/18
04/20
06:12
04/20/18
06:12
Downgrade
Procter & Gamble rating change  »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SWK

Stanley Black & Decker

$154.68

-2.715 (-1.73%)

06:08
04/20/18
04/20
06:08
04/20/18
06:08
Hot Stocks
Stanley Black & Decker CEO say Q1 organic growth up 4% »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 04

    Jun

MAT

Mattel

$13.44

-0.45 (-3.24%)

06:08
04/20/18
04/20
06:08
04/20/18
06:08
Hot Stocks
Ancestry names Margo Georgiadis as CEO »

Ancestry announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

CLNE

Clean Energy

$1.64

-0.015 (-0.91%)

06:07
04/20/18
04/20
06:07
04/20/18
06:07
Hot Stocks
Clean Energy to build three CNG stations in Ontario for Union Energy Solutions »

Clean Energy Fuels has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADMS

Adamas Pharmaceuticals

$27.68

1.82 (7.04%)

06:06
04/20/18
04/20
06:06
04/20/18
06:06
Recommendations
Adamas Pharmaceuticals analyst commentary  »

Adamas positioned for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 12

    Jun

SWK

Stanley Black & Decker

$154.68

-2.715 (-1.73%)

06:06
04/20/18
04/20
06:06
04/20/18
06:06
Earnings
Stanley Black & Decker backs FY18 adj. EPS view of $8.30-$8.50, consensus $8.43 »

Management is revising…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 04

    Jun

ROP

Roper Technologies

$279.93

0.195 (0.07%)

06:05
04/20/18
04/20
06:05
04/20/18
06:05
Earnings
Breaking Earnings news story on Roper Technologies »

Roper Technologies sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 16

    May

RF

Regions Financial

$18.15

0.25 (1.40%)

06:04
04/20/18
04/20
06:04
04/20/18
06:04
Hot Stocks
Regions Financial sees gain of $200M from sale of Regions Insurance subsidiary »

Subsequent to the end of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

ROP

Roper Technologies

$279.93

0.195 (0.07%)

06:04
04/20/18
04/20
06:04
04/20/18
06:04
Earnings
Roper Technologies raises FY18 adj EPS view to $11.08-$11.32 from $10.88-$11.20 »

Consensus for FY18 EPS is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 16

    May

CYD

China Yuchai

$22.31

-0.68 (-2.96%)

06:03
04/20/18
04/20
06:03
04/20/18
06:03
Hot Stocks
China Yuchai announces 800 buses exported to Saudi Arabia »

China Yuchai, through its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCS

Barclays

$12.26

0.045 (0.37%)

06:03
04/20/18
04/20
06:03
04/20/18
06:03
Hot Stocks
FCA, PRA conclude investigations into Barclays, CEO Jes Staley »

As announced on April 10,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$154.68

-2.715 (-1.73%)

06:03
04/20/18
04/20
06:03
04/20/18
06:03
Earnings
Stanley Black & Decker reports Q1 EPS ex-items $1.39, consensus $1.36 »

Reports Q1 revenue $3.2B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 04

    Jun

ROP

Roper Technologies

$279.93

0.195 (0.07%)

06:03
04/20/18
04/20
06:03
04/20/18
06:03
Earnings
Roper Technologies reports Q1 adjusted EPS $2.61, consensus $2.49 »

Reports Q1 revenue $1.2B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 16

    May

PM

Philip Morris

$85.65

-15.86 (-15.62%)

06:02
04/20/18
04/20
06:02
04/20/18
06:02
Downgrade
Philip Morris rating change  »

Philip Morris downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

RF

Regions Financial

$18.15

0.25 (1.40%)

06:02
04/20/18
04/20
06:02
04/20/18
06:02
Hot Stocks
Breaking Hot Stocks news story on Regions Financial »

Regions Financial reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

STI

SunTrust

$66.98

1.555 (2.38%)

06:02
04/20/18
04/20
06:02
04/20/18
06:02
Earnings
SunTrust reports Q1 EPS $1.29, consensus $1.11 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 26

    Apr

  • 30

    May

PG

Procter & Gamble

$74.98

-2.4928 (-3.22%)

06:02
04/20/18
04/20
06:02
04/20/18
06:02
Downgrade
Procter & Gamble rating change  »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

RF

Regions Financial

$18.15

0.25 (1.40%)

06:00
04/20/18
04/20
06:00
04/20/18
06:00
Earnings
Regions Financial reports Q1 cont ops EPS 35c, consensus 31c »

Reports Q1 revenue $1.4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

LEVL

Level One

06:00
04/20/18
04/20
06:00
04/20/18
06:00
Syndicate
Level One 1.2M share IPO priced at $28.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

MDSO

Medidata

$73.45

3.7 (5.30%)

05:56
04/20/18
04/20
05:56
04/20/18
05:56
Recommendations
Medidata analyst commentary  »

Medidata subscription…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 09

    May

TEAM

Atlassian

$62.24

0.18 (0.29%)

05:36
04/20/18
04/20
05:36
04/20/18
05:36
Recommendations
Atlassian analyst commentary  »

Atlassian business…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 12

    Jun

WING

Wingstop

$50.92

-0.37 (-0.72%)

05:34
04/20/18
04/20
05:34
04/20/18
05:34
Initiation
Wingstop initiated  »

Wingstop initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

TWTR

Twitter

$31.54

-0.01 (-0.03%)

05:34
04/20/18
04/20
05:34
04/20/18
05:34
Upgrade
Twitter rating change  »

Twitter upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.